<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/19967012-2023-2-57-64</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1410</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Длительное многоцентровое наблюдательное исследование Алфлутопа в России: предварительные результаты (сообщение 1)</article-title><trans-title-group xml:lang="en"><trans-title>Alflutop Russian longitudinal multicentre observational study: preliminary results (message 1)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра ревматологии Российская МАНПО.</p><p>115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Department of Rheumatology RMACPE</p><p>34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7017-0898</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Ивановна Алексеева</p><p>115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Lyudmila Ivanovna Alekseeva</p><p>34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993</p></bio><email xlink:type="simple">dr.alekseeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8218-3223</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таскина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Taskina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8732-2720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашеварова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kashevarova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2023</year></pub-date><volume>17</volume><issue>2</issue><fpage>57</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лила А.М., Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Лила А.М., Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г.</copyright-holder><copyright-holder xml:lang="en">Lila A.M., Alekseeva L.I., Taskina E.A., Kashevarova N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1410">https://mrj.ima-press.net/mrj/article/view/1410</self-uri><abstract><p>Оценка действия новых лекарственных препаратов должна проводиться в рандомизированных контролируемых исследованиях (РКИ), а наблюдательные исследования (НИ) осуществляются для подтверждения и уточнения результатов, полученных в РКИ, например для изучения эффективности препаратов в больших группах больных, которые не включены в РКИ или имели сопутствующие заболевания либо более старший возраст.</p><p>Цель исследования – в НИ оценить эффективность терапии препаратом Алфлутоп (АФ) у пациентов с остеоартритом (ОА) коленных, и/или тазобедренных суставов, и/или болью в нижней части спины (БНЧС) при наличии или отсутствии коморбидных заболеваний.</p><sec><title>Материал и методы</title><p>Материал и методы.Многоцентровое проспективное когортное НИ проводилось в 163 клинических центрах 58 городов Российской Федерации и включало 22 525 больных ОА и БНЧС, которые получали АФ по назначению врача в рамках планового лечения или самостоятельно приобретали его в аптеке. Регистрировались боль, удовлетворенность терапией, оценка состояния здоровья, потребность в нестероидных противовоспалительных препаратах (НПВП) и качество жизни по опроснику EQ-5D.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение.После одного курса лечения АФ улучшение выявлено в 98% случаев, отмечалась быстрая положительная динамика со значимым уменьшением боли, медиана времени до получения клинического эффекта составила 8 [5; 10] дней. Существенно улучшились оценка состояния здоровья и удовлетворенность терапией. У 94,5% пациентов снизилась суточная потребность в НПВП.</p></sec><sec><title>Заключение</title><p>Заключение. Первые результаты НИ подтверждают симптоматический эффект АФ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Evaluation of the effect of new drugs should be carried out in randomized controlled trials (RCTs), and observational studies (OSs) are carried out to confirm and refine the results obtained in RCTs, for example, to study the effectiveness of drugs in large groups of patients who were not included in RCTs or had comorbidities or older age.</p><sec><title>Objective</title><p>Objective: to evaluate the effectiveness of Alflutop (AF) via OS of patients with osteoarthritis (OA) of the knee and/or hip joints and/or low back pain (LBP) with or without comorbid diseases.</p></sec><sec><title>Material and methods</title><p>Material and methods. A multicenter prospective cohort OS was conducted in 163 clinical centers in 58 cities of the Russian Federation and included 22,525 patients with OA and LBP who received AF as a part of a planned treatment prescribed by a doctor, or self-prescribed and purchased in a pharmacy. Pain, satisfaction with therapy, health assessment, need for non-steroidal anti-inflammatory drugs (NSAIDs), and quality of life were recorded using the EQ-5D questionnaire.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. After one treatment course with AF, improvement was detected in 98% of cases, there was a rapid positive trend with a significant decrease in pain, the median time to clinical effect was 8 [5; 10] days. Assessment of general health status and satisfaction with therapy improved significantly. In 94.5% of patients, the daily requirement for NSAIDs decreased.</p></sec><sec><title>Conclusion</title><p>Conclusion. The first results from the OS confirm the symptomatic effect of AF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>Алфлутоп</kwd><kwd>наблюдательное исследование</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>Alflutop</kwd><kwd>observational study</kwd><kwd>efficiency</kwd><kwd>safety</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28;396(10264): 1711-2. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.</mixed-citation><mixed-citation xml:lang="en">Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020 Nov 28;396(10264): 1711-2. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ackerman IN, Kemp JL, Crossley KM, et al. Hip and knee osteoarthritis affects younger people, too. J Orthop Sports Phys Ther. 2017 Feb;47(2):67-79. doi: 10.2519/jospt.2017.7286.</mixed-citation><mixed-citation xml:lang="en">Ackerman IN, Kemp JL, Crossley KM, et al. Hip and knee osteoarthritis affects younger people, too. J Orthop Sports Phys Ther. 2017 Feb;47(2):67-79. doi: 10.2519/jospt.2017.7286.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi: 10.1016/S0140-6736(20)30925-9.</mixed-citation><mixed-citation xml:lang="en">GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-22. doi: 10.1016/S0140-6736(20)30925-9.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">https://ourworldindata.org/burdenof-disease</mixed-citation><mixed-citation xml:lang="en">https://ourworldindata.org/burdenof-disease</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020 Jun;79(6):819-28. doi: 10.1136/annrheumdis-2019-216515. Epub 2020 May 12.</mixed-citation><mixed-citation xml:lang="en">Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020 Jun;79(6):819-28. doi: 10.1136/annrheumdis-2019-216515. Epub 2020 May 12.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Cleveland RJ, Alvarez C, Schwartz TA, et al. The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up. Osteoarthritis Cartilage. 2019 Apr 1;27(4):593e602. doi.org/10.1016/j.joca.2018.12.008.</mixed-citation><mixed-citation xml:lang="en">Cleveland RJ, Alvarez C, Schwartz TA, et al. The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up. Osteoarthritis Cartilage. 2019 Apr 1;27(4):593e602. doi.org/10.1016/j.joca.2018.12.008.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum.2012 Jun;64(6):1697e707. doi: 10.1002/art.34453.</mixed-citation><mixed-citation xml:lang="en">Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum.2012 Jun;64(6):1697e707. doi: 10.1002/art.34453.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">BEST (Biomarkers, EndpointS, and other Tools) Resource. https://www.ncbi.nlm.nih.gov/books/NBK326791.</mixed-citation><mixed-citation xml:lang="en">BEST (Biomarkers, EndpointS, and other Tools) Resource. https://www.ncbi.nlm.nih.gov/books/NBK326791.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.medtran.ru/rus/trials/clinicaltrials.htm</mixed-citation><mixed-citation xml:lang="en">https://www.medtran.ru/rus/trials/clinicaltrials.htm</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D, Bakhai A. Clinical trials. A practical guide to design, analysis and reporting. London; 2006. 480 p.</mixed-citation><mixed-citation xml:lang="en">Wang D, Bakhai A. Clinical trials. A practical guide to design, analysis and reporting. London; 2006. 480 p.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008.</mixed-citation><mixed-citation xml:lang="en">Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W, Sun C, He SQ, et al. The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis — a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021 Jul;36(7): 2085-93. doi: 10.1007/s11606-021-06755-z. Epub 2021 Apr 12.</mixed-citation><mixed-citation xml:lang="en">Yang W, Sun C, He SQ, et al. The Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis — a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021 Jul;36(7): 2085-93. doi: 10.1007/s11606-021-06755-z. Epub 2021 Apr 12.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen C, Guo-Feng B, Guanhua X , et al. Altered Wnt and NF-κB Signaling in Facet Joint Osteoarthritis: Insights from RNA Deep Sequencing. Tohoku J Exp Med. 2018 May; 245(1):69-77. doi: 10.1620/tjem.245.69.</mixed-citation><mixed-citation xml:lang="en">Chen C, Guo-Feng B, Guanhua X , et al. Altered Wnt and NF-κB Signaling in Facet Joint Osteoarthritis: Insights from RNA Deep Sequencing. Tohoku J Exp Med. 2018 May; 245(1):69-77. doi: 10.1620/tjem.245.69.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Jul;12(7):412-20. doi: 10.1038/nrrheum.2016.65. Epub 2016 May 19.</mixed-citation><mixed-citation xml:lang="en">Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Jul;12(7):412-20. doi: 10.1038/nrrheum.2016.65. Epub 2016 May 19.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Олариу Л, Димитриу Б, Мануэла Эне Д и др. In vitro влияние препарата Алфлутоп на механизмы развития остеоартрита. Вестник Академии румынских ученых. 2017;(6)1:82-99.</mixed-citation><mixed-citation xml:lang="en">Olariu L, Dimitriu B, Manuela Ene D, et al. In vitro effect of Alflutop on the mechanisms of osteoarthritis development. Vestnik Akademii rumynskikh uchenykh. 2017;(6)1:82-99. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ. Биоактивный концентрат мелкой морской рыбы: оценка эффективности и безопасности препарата на основании анализа 37 клинических исследований. Современная ревматология. 2020; 14(4);111-24. doi: 10.14412/1996-7012-2020-4-111-124.</mixed-citation><mixed-citation xml:lang="en">Karateev AE. Bioactive concentrate from small sea fish: Evaluation of the efficacy and safety of the drug on the basis of the analysis of 37 clinical trials. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020; 14(4):111-24. (In Russ.). doi: 10.14412/1996-7012-2020-4-111-124.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ, Шарапова ЕП, Таскина ЕА и др. Многоцентровое слепое рандомизированное плацебо-контролируемое исследование симптоми структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 1 – оценка симптоммодифицирующего действия препарата. Научно-практическая ревматология. 2013; 51(5);532-8.</mixed-citation><mixed-citation xml:lang="en">Alekseeva LI, Sharapova EP, Taskina EA, et al. Multicenter double-blind randomized placebo-controlled trial of the symptomand structure-modifying effect of Alflutop in patients with knee osteoarthrosis. Communication 1. Evaluation of the symptom-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2013;51(5):532-8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ, Шарапова ЕП, Таскина ЕА и др. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптоми структурно-модифицирующего действия препарата Алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 – оценка структурно-модифицирующего действия препарата. Научно-практическая ревматология. 2014;52(2);174-7.</mixed-citation><mixed-citation xml:lang="en">Alekseeva LI, Sharapova EP, Taskina EA, et al. A multicenter, blind, randomized, placebo-controlled study of the symptomand structure-modifying effect of Alflutop in patients with knee osteoarthritis. Report 2: The assessment of the structure-modifying effect of the drug. Nauchno-Prakticheskaya Revmatologia. 2014;52(2):174-7. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
